HTL Biotechnology and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools
HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005119/en/
HTL's campus is located in Paris, France. HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products. https://htlbiotech.com/
The partnership provides academic research and pharmaceutical development laboratories’ expanded access to Good Manufacturing Practices (GMP)-grade, kit-packaged hyaluronic acid and glycosaminoglycan (GAG) products. By offering premium, clinical grade products to early-stage research investigators, the partnership seeks to bridge the gap between lab-based research, development and commercialization, and accelerate innovation worldwide.
“Innovation is at the heart of HTL’s DNA,” said HTL CEO Yvon Bastard. “This growth opportunity reinforces our mission and vision to apply science for increased bio-compatibility and improved health outcomes around the world.”
“This new partnership offers scientists and researchers the key technologies to develop innovative biopolymer solutions for new medical applications in aesthetics, ophthalmology, rheumatology, tissue engineering and drug delivery,” said Charles Ruban, HTL deputy CEO. “This is the true meaning of HTL’s tagline of ‘Beyond, together.’ HTL’s ambition is not only to grow its lead position in producing and distributing hyaluronic acid worldwide, but also to build tomorrow’s glycosaminoglycan-based solutions.”
“Echelon has been granted the opportunity to expand its market-leading HA assays and extra cellular matrix product line with the supply of HTL’s hyaluronic acid and other GAG-derived products. HTL is recognized internationally for producing biopolymers of premium quality,” says Bert Israelsen, president of Echelon Biosciences. “Echelon offers our customers access to the latest innovative tools with unparalleled technical support, thereby fully enabling maximized creativity in basic and applied research. With its fermentation and organic synthesis platforms, HTL creates functionality and added value by developing chemically modified biopolymers tailored to specific needs.”
“This new partnership is a milestone in HTL’s expanding footprint in the North American market and with the U.S. medical community,” said Glenn Prestwich, Ph.D., one of Echelon’s founders and now HTL’s exclusive science and innovation advisor for this market. By entrusting Echelon with the distribution of HTL’s hyaluronic acid and glycosaminoglycan products for research use, HTL aims to significantly increase its support and involvement in biopolymer research in the U.S. and worldwide, but also its research and development capacity.
“This new initiative demonstrates HTL’s commitment to invest in innovation in healthcare,” said Humberto C. Antunes, strategic advisor to HTL and former CEO of Galderma. “In the fields of health and wellness, the biotechnology ecosystem of innovation, incubators, and established and emerging companies are incredibly dynamic in the United States, Mexico and Canada. It means a huge growth potential for HTL products,” added Antunes.
About HTL
HTL is a biotechnology company, leading the way in the design and production of pharmaceutical grade hyaluronic acid and other innovative functional biopolymers for premium medical products. HTL serves the pharmaceutical and medical device industries worldwide, enabling them to transform lives of patients. HTL’s unsurpassed commitment to client partnership has been consistently proven in the marketplace. The company is recognized for supplying the highest quality products and continually investing in driving and supporting market growth. For over 25 years, its cutting-edge research and development has allowed to develop unique value-driven solutions to meet the innovation needs of its clients.
About Echelon Biosciences, Inc.
Based in Salt Lake City, Utah, Echelon Biosciences, was established in 1997 to supply synthetic lipid reagents for research and development. Since then, Echelon has successfully grown in scale and scope to include custom chemistry, peptides, and biological assays with over 700 catalog items in the fields of cell signaling, extracellular matrix, cancer drug discovery, and disease biomarkers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005119/en/
Contact information
HTL
Dianne Danowski Smith, APR – Publix Northwest PR + PA
+1.503.201.7019 - dianne@publixnw.com
Echelon Biosciences, Inc.
Mark Nelson, PhD - Vice President Business and Science Development
+1 801-588-0455 - mnelson@echelon-inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv811.12.2025 15:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chronic mechanical low back pain associated with multifidus muscle dysfunction. ReActiv8® restorative neurostimulation is the only therapy approved in the United States, Europe and Australia for this indication. The Statement, which affirms ISASS’ support for coverage by payers of implantable restorative neurostimulation in appropriately selected patients, was published in the December issue of the International Journal of Spine Surgery and can be accessed here: https://www.ijssurgery.com/content/early/2025/12/10/8833. The Statement reflects the growing body of clinical evidence supporting the use of ReActiv8, as well as recent developments in diagnostic coding and reimbursement pathways since ISASS’ 2023 Statement on Restorative Neurostimulation for Chr
SLB Enters Collaboration Agreement to Accelerate New Digital Solutions11.12.2025 15:28:00 EET | Press release
Global energy technology company SLB (NYSE: SLB) signed a strategic collaboration agreement with Shell to develop digital and AI solutions that drive measurable performance and efficiency gains across upstream operations for the company and the wider industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211832051/en/ The collaboration has the ambition to develop agentic AI-powered solutions that will accelerate and amplify the capabilities of technical experts and decision makers. The aim is to develop and deploy an open data and AI infrastructure that unifies data and workflows across subsurface, well construction and production in a secure digital environment, using SLB’s Lumi™ data and AI platform. The collaboration has the ambition to develop agentic AI-powered solutions that will accelerate and amplify the capabilities of technical experts and decision makers. The aim is to develop and deploy an open data and AI i
Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas11.12.2025 15:00:00 EET | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcoming 300M cell project. Tahoe will use its proprietary Mosaic technology to generate samples consisting of 300M cells from large arrays of disease models, genetically or chemically perturbed. Under this agreement, Parse will apply its Evercode™ chemistry and high-throughput automation to these samples to deliver the largest perturbation-focused single cell dataset ever produced. Parse’s GigaLab, designed specifically for million- to hundred-million-cell projects, has rapidly become an industry benchmark for large-scale, reproducible single cell data generation. The facility integrates high-capacity liquid handling, standardized workflows, and end-to-end QC to enable dataset sizes previously unattainable for most research organizations. The Tahoe project represents one of the largest sequencin
Xsight Labs X2 Switch to Enable Next-Generation Starlink Satellites and Deliver Gigabit Connectivity11.12.2025 15:00:00 EET | Press release
Xsight Labs, an innovator in high-performance connectivity silicon, today announced that Starlink, the world’s most advanced satellite constellation in low-Earth orbit, delivering broadband, will leverage the Xsight X2 Programmable Ethernet switch to serve as the high-speed networking core for its next-generation Starlink V3 satellites. Each V3 Starlink satellite is designed to deliver more than 1 terabit per second (Tbps) of fronthaul throughput, more than 10× the capacity delivered by Starlink V2 Mini satellites, and about 160 gigabits per second (Gbps) of uplink capacity. Starlink’s global broadband service depends on processing and routing large volumes of real-time data, including inter-satellite optical link traffic, orbital mesh routing decisions, adaptive beam steering, and the high-throughput downlink required to serve its customers. The X2 delivers 12.8 Tbps of switching capacity using state-of-the-art 100G SerDes and TSMC’s N5 process, providing a power-efficient, ultra-low-
Payments Leaders Unprepared for 2026 Disruption, Warns ACI Worldwide11.12.2025 14:36:00 EET | Press release
Most global payments leaders lack a clear roadmap to navigate the seismic changes coming in 2026 , according to the latest Top Ten Payments Predictions from ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology. With AI-driven intelligence, next-gen authentication, new regulatory frameworks, and soaring demand for instant, embedded, and secure payments, the industry is entering an era of structural disruption. However, ACI’s recent report Payments in Transition: Leadership in an era of transformation reveals that only 36% of payments executives have a clear long-term modernization roadmap, leaving many without a strategic vision for transformation. “In 2026, payments disruption won’t be incremental—it will be structural,” said Philip Bruno, Chief Strategy and Growth Officer at ACI Worldwide. “Real-time is now the baseline, digital assets are entering regulated ecosystems, and AI is transforming every layer of the value chain. Our research is a clear warning:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom